Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Pancreatic Neoplasms × onvansertib × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 1 Pancreatic Neoplasms 1 Leukemia, Myeloid, Acute 1 Inflammatory Breast Neoplasms 1 Colorectal Neoplasms 1 Breast Neoplasms 1

Interventions

Gemcitabine 87 130-nm albumin-bound paclitaxel 44 Albumin-Bound Paclitaxel 34 Oxaliplatin 25 Fluorouracil 25 Capecitabine 20 Leucovorin 19 Taxes 18 pembrolizumab 16 Irinotecan 16 Cyclophosphamide 16 Cetuximab 11 Bevacizumab 11 Nivolumab 10 Cisplatin 10 fludarabine 9 durvalumab 7 aldesleukin 7 Radiotherapy 7 spartalizumab 6 Radiosurgery 6 Paclitaxel 6 irinotecan sucrosofate 5 avelumab 5 Injections 5 Erlotinib Hydrochloride 5 ALT-803 5 folfirinox 4 dehydroftorafur 4 Ipilimumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06736717 2025-02-06

PANCONVA

University of Kansas Medical Center

Phase 1/2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡